Wegovy vs Zepbound: What the Research Actually Says About Which Wins for Weight Loss

When two blockbuster weight loss drugs go head-to-head, the numbers matter. A 2024 JAMA Internal Medicine cohort study analyzing over 18,000 propensity score-matched adults found that tirzepatide — the active ingredient in Zepbound — made patients 3.24 times more likely to achieve 15% or greater body weight loss compared to semaglutide, the drug behind Wegovy. At 12 months, tirzepatide users lost an average of 6.9 percentage points more body weight. That is not a rounding error. That is a clinically meaningful gap. But before you call your doctor demanding a prescription switch, there is more context worth understanding.

How These Two Drugs Actually Work

Semaglutide (Wegovy) is a GLP-1 receptor agonist. It mimics a gut hormone that signals fullness to the brain, slows gastric emptying, and blunts appetite. It does this through a single receptor pathway, and it does it well. Tirzepatide (Zepbound) takes a different approach entirely. As research published in Cardiovascular Diabetology explains, tirzepatide is a dual GIP/GLP-1 receptor co-agonist — an acylated peptide engineered to activate both the GIP and GLP-1 receptors simultaneously. GIP receptors are expressed in brain regions that regulate food intake, and activating them alongside GLP-1 appears to produce a synergistic appetite-suppressing and metabolic effect that a single-receptor drug simply cannot replicate. That dual mechanism is the biological reason behind tirzepatide’s edge on the scale.

A 2024 systematic review and network meta-analysis in Diabetologia examining 28 randomized controlled trials with over 23,000 participants confirmed this pattern, finding tirzepatide 15mg to be the most efficacious treatment in reducing both HbA1c and body weight compared to all doses of subcutaneous semaglutide tested. The data consistently point in one direction: if the goal is maximum weight reduction, tirzepatide has a pharmacological advantage.

Where Semaglutide Still Holds Its Ground

Raw weight loss numbers are not the whole story. A 2025 systematic review in Annals of Internal Medicine covering 26 randomized controlled trials and nearly 15,500 participants confirmed that both GLP-1 receptor agonists and dual co-agonists are highly efficacious for weight loss in adults without diabetes, with safety concerns predominantly gastrointestinal and comparable between drug classes. In plain terms — both drugs work, both carry similar nausea risk, and both are meaningful tools for men dealing with obesity or metabolic dysfunction.

The cardiovascular picture is particularly important here. A 2025 JAMA study examining over 28,000 patients with heart failure with preserved ejection fraction found that semaglutide reduced the composite risk of hospitalization or all-cause mortality by 42% compared to placebo — and when tirzepatide was put head-to-head against semaglutide in this population, it showed no meaningful additional benefit. The hazard ratio was 0.86 with confidence intervals crossing 1.0. For men with cardiometabolic HFpEF specifically, both drugs appear to offer substantial protection, but tirzepatide does not clearly pull ahead. This matters because weight loss is rarely the only goal — cardiovascular risk reduction often sits at the top of the priority list.

Cost, insurance coverage, and access are also real-world variables the clinical trials do not account for. Wegovy has a longer track record with payers and is more widely covered in many insurance plans. Zepbound, newer to the obesity indication market, is still working through formulary negotiations. For men who would benefit from either drug, the one you can actually afford and consistently obtain beats the one that looks better on paper.

The Takeaway

If you are deciding between Wegovy and Zepbound with your physician, the research gives tirzepatide a meaningful edge for total weight loss — roughly 6 to 7 percentage points more at 12 months in real-world data, with a far higher likelihood of hitting the 15% loss threshold that tends to produce durable metabolic improvements. That advantage is rooted in its dual-receptor mechanism and backed by multiple large analyses. But semaglutide is not a consolation prize. It delivers substantial weight loss, strong cardiovascular protection, and a more established coverage footprint. The best drug is the one you tolerate well, can access consistently, and that your doctor agrees fits your metabolic profile. Whichever route you take, pairing either medication with resistance training and adequate protein intake remains non-negotiable — the drug creates the caloric deficit, but protecting muscle through that deficit is still your job.